Compare Heron Therapeutics Inc (HRTX) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Quanta Services Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Quanta Services Inc trades at $691 (market cap $103.03B). The key difference: Quanta Services Inc is far larger — about 1514.9× Heron Therapeutics Inc's market cap, and Quanta Services Inc pays a 0.06% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Quanta Services Inc for 62 Days on average.
| HRTX | PWR | |
|---|---|---|
Market Cap | $68.01M | $103.03B |
Volume | 1,891,941 | 977,892 |
Sector | Health | Industrials |
52-Week High | $1.49 | $785.24 |
52-Week Low | $0.27 | $412.21 |
Typical Hold Time | 35 Days | 62 Days |
Enterprise Value | $174.75M | $109.13B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Quanta Services (PWR) trades at $701.07, down 2.57% on the day, but maintains a bullish technical outlook with strong analyst support. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $4.24 surpassing the $3.31 forecast. Revenue growth is robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins remain modest at 4.03%. A record $53B backlog and positive media coverage on AI infrastructure demand highlight operational strength.
The investment outlook is positive, driven by earnings momentum and sector tailwinds, but high valuation multiples (P/E 80.21) and execution risks on large projects pose challenges. The consensus price target of $802.08 implies significant upside, supported by 27 buy ratings and no sell recommendations from analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
